These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 30713788)
1. ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. Gao M; Lin Y; Liu X; Li Y; Zhang C; Wang Z; Wang Z; Wang Y; Guo Z Oncoimmunology; 2019; 8(2):e1534038. PubMed ID: 30713788 [TBL] [Abstract][Full Text] [Related]
2. Gao M; Lin Y; Liu X; Zhao Z; Zhu Z; Zhang H; Ban Y; Bie Y; He X; Sun X; Zhang S Front Cell Dev Biol; 2021; 9():654407. PubMed ID: 33996815 [TBL] [Abstract][Full Text] [Related]
3. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma. Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245 [TBL] [Abstract][Full Text] [Related]
4. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas. Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J Front Oncol; 2021; 11():611038. PubMed ID: 33937022 [TBL] [Abstract][Full Text] [Related]
5. Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma. Peng Y; Liu H; Wu Q; Wang L; Yu Y; Yin F; Feng C; Ren X; Liu T; Chen L; Zhu H BMC Cancer; 2023 Jun; 23(1):596. PubMed ID: 37380984 [TBL] [Abstract][Full Text] [Related]
6. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling. Long S; Li M; Liu J; Yang Y; Li G Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827 [TBL] [Abstract][Full Text] [Related]
7. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma. Chen Y; Guo Y; Chen H; Ma F Front Neurol; 2020; 11():573264. PubMed ID: 33329315 [No Abstract] [Full Text] [Related]
8. CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways. Wang Z; Zhang J; Zhang H; Dai Z; Liang X; Li S; Peng R; Zhang X; Liu F; Liu Z; Yang K; Cheng Q Front Cell Dev Biol; 2022; 10():740822. PubMed ID: 35252165 [TBL] [Abstract][Full Text] [Related]
9. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734 [No Abstract] [Full Text] [Related]
10. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas. Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770 [TBL] [Abstract][Full Text] [Related]
11. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses. Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC Front Oncol; 2019; 9():1433. PubMed ID: 31921684 [No Abstract] [Full Text] [Related]
12. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients. Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935 [TBL] [Abstract][Full Text] [Related]
14. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma. Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523 [TBL] [Abstract][Full Text] [Related]
15. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919 [TBL] [Abstract][Full Text] [Related]
16. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110 [TBL] [Abstract][Full Text] [Related]
17. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222 [TBL] [Abstract][Full Text] [Related]
18. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
19. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210 [TBL] [Abstract][Full Text] [Related]
20. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis. Xu Z; Chen X; Song L; Yuan F; Yan Y Front Immunol; 2022; 13():834595. PubMed ID: 35281049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]